drugset / Trial / NCT04970108

Efficacy and Safety of Egito Association in the Treatment of Type II Diabetes Mellitus and Hypertension

NCT04970108

Phase 3 Withdrawn EMS
RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this study is to evaluate the efficacy and safety of Egito association in the treatment of type 2 diabetes mellitus and hypertension

Timeline

Start
2023-08
Primary completion
2025-01
Completion
2025-05

Drugs

EvaluationDrugModalityDoseRoute
Subject Egito Unknown Oral
Comparator Empagliflozin Small molecule 25 mg Oral
Comparator Telmisartan Other / unclassified 40 mg Oral
Comparator Telmisartan Other / unclassified 80 mg Oral